Business

Actinogen confirms 100th participant in XanaMIA phase 2b/3 Alzheimer's disease trial and interim analysis timeline

Actinogen Medical Limited (ASX: ACW) announces that the 100th participant in its pivotal XanaMIA phase 2b/3 randomized trial of Xanamem® for Alzheimer's disease (AD) has now passed all screening tests and is scheduled for randomization and treatment in July.